AVTX · Avalo Therapeutics, Inc.
$19.82
-0.93 (-4.48%)
At close · Aug 20
Market Cap
$1.06B
Shares
53.63M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$19.82
Open$20.38
Day$19.49–20.59
52W close$9.02–22.87
Avg vol 30d799K
Short int13.0M · 24.1% float · 14.4d
Short vol66%
DataDec 2023–Aug 2026
Filing10-Q · Aug 6
Raw chart and full-history price indicators begin at the captured split on Dec 29, 2023; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+19%
above
Price vs 50-day avg
+9%
above
RSI (14)
55
neutral
MACD trend
Positive
52-week position
78%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+12%
trailing
6-month return
+13%
trailing
YTD return
+9%
this year
Relative strength
+2%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $18 › 200d $17 — 50d above 200d
Institutional flow
Accumulating
+26% holders QoQ · +53 funds added
Insider flow
Distributing
Net -$52.0K over 90 days · 100% sells
Short interest
Rising
24.15% of float · ▲ +2.1% MoM · 14.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
127 holders — near 3-yr high, broad support
Squeeze score
82
high risk · 0–100
Fundamentals
Revenue growth
+2312%
Y/Y
EPS growth
+72%
Y/Y
Free cash flow
$-51.6M
Balance sheet
$480.1K
net cash
Quant / Vol
risk profile
Volatility
89%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
5.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+19%
Bullish
Price vs 50-day avg
+9%
Bullish
RSI (14)
55
Neutral
MACD trend
Positive
Bullish
52-week position
78%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $18 › 200d $17 — 50d above 200d
Institutional flow
Accumulating
+26% holders QoQ · +53 funds added
Insider flow
Distributing
Net -$52.0K over 90 days · 100% sells
Short interest
Rising
24.15% of float · ▲ +2.1% MoM · 14.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
127 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $9
Now $20 · 78%
Range high $23
vs 200-day avg +19%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AVTX
this stock
Avalo Therapeutics, Inc.
|
$1.06B | +9.1% | +2312.3% | — | 24.1% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Performance
Raw-price comparisons begin at the captured split on Dec 29, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AVTX | +1.9% | +11.6% | +13.3% | +8.6% | +9.1% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +3.9% | +8.3% | +2.1% | +6.5% | -2.7% |
Key facts
CIK
1534120
CUSIP
05338F306
13F (30d)
135 filings
125 filers
Visit website
Investor relations